SG11201805831RA - Neutralization of inhibitory pathways in lymphocytes - Google Patents
Neutralization of inhibitory pathways in lymphocytesInfo
- Publication number
- SG11201805831RA SG11201805831RA SG11201805831RA SG11201805831RA SG11201805831RA SG 11201805831R A SG11201805831R A SG 11201805831RA SG 11201805831R A SG11201805831R A SG 11201805831RA SG 11201805831R A SG11201805831R A SG 11201805831RA SG 11201805831R A SG11201805831R A SG 11201805831RA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- marseille
- nkg2a
- avenue
- pct
- Prior art date
Links
- 230000002401 inhibitory effect Effects 0.000 title abstract 2
- 210000004698 lymphocyte Anatomy 0.000 title abstract 2
- 238000006386 neutralization reaction Methods 0.000 title abstract 2
- 230000037361 pathway Effects 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 230000003472 neutralizing effect Effects 0.000 abstract 2
- 101000706020 Nicotiana tabacum Pathogenesis-related protein R minor form Proteins 0.000 abstract 1
- 235000001466 Ribes nigrum Nutrition 0.000 abstract 1
- 241001312569 Ribes nigrum Species 0.000 abstract 1
- LUTSRLYCMSCGCS-BWOMAWGNSA-N [(3s,8r,9s,10r,13s)-10,13-dimethyl-17-oxo-1,2,3,4,7,8,9,11,12,16-decahydrocyclopenta[a]phenanthren-3-yl] acetate Chemical compound C([C@@H]12)C[C@]3(C)C(=O)CC=C3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)C)C1 LUTSRLYCMSCGCS-BWOMAWGNSA-N 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662281217P | 2016-01-21 | 2016-01-21 | |
| PCT/EP2017/051153 WO2017125532A1 (en) | 2016-01-21 | 2017-01-20 | Neutralization of inhibitory pathways in lymphocytes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201805831RA true SG11201805831RA (en) | 2018-08-30 |
Family
ID=57944387
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201805831RA SG11201805831RA (en) | 2016-01-21 | 2017-01-20 | Neutralization of inhibitory pathways in lymphocytes |
| SG10202000645SA SG10202000645SA (en) | 2016-01-21 | 2017-01-20 | Neutralization of Inhibitory Pathways in Lymphocytes |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202000645SA SG10202000645SA (en) | 2016-01-21 | 2017-01-20 | Neutralization of Inhibitory Pathways in Lymphocytes |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US10870700B2 (sr) |
| EP (2) | EP3405495B1 (sr) |
| JP (2) | JP7301538B2 (sr) |
| KR (1) | KR20180101549A (sr) |
| CN (2) | CN108884163B (sr) |
| AU (2) | AU2017208554B2 (sr) |
| CA (1) | CA3012055A1 (sr) |
| CY (1) | CY1124212T1 (sr) |
| DK (1) | DK3405495T3 (sr) |
| ES (1) | ES2871112T3 (sr) |
| HR (1) | HRP20210778T1 (sr) |
| HU (1) | HUE054356T2 (sr) |
| IL (1) | IL260464B (sr) |
| LT (1) | LT3405495T (sr) |
| PL (1) | PL3405495T3 (sr) |
| PT (1) | PT3405495T (sr) |
| RS (1) | RS61901B1 (sr) |
| RU (1) | RU2769569C2 (sr) |
| SG (2) | SG11201805831RA (sr) |
| SI (1) | SI3405495T1 (sr) |
| WO (1) | WO2017125532A1 (sr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3409289B1 (en) | 2010-02-26 | 2020-09-30 | Novo Nordisk A/S | Stable antibody containing compositions |
| US9512228B2 (en) | 2011-06-17 | 2016-12-06 | Novo Nordisk A/S | Selective elimination of erosive cells |
| CA2974651A1 (en) | 2014-01-24 | 2015-07-30 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Smc combination therapy for the treatment of cancer |
| SG11201701387SA (en) | 2014-09-16 | 2017-03-30 | Innate Pharma | Treatment regimens using anti-nkg2a antibodies |
| SG11201701340RA (en) | 2014-09-16 | 2017-03-30 | Innate Pharma | Neutralization of inhibitory pathways in lymphocytes |
| EP3659625A1 (en) | 2014-10-23 | 2020-06-03 | Innate Pharma | Treatment of cancers using anti-nkg2a agents |
| AU2016299166B2 (en) | 2015-07-24 | 2022-03-31 | Innate Pharma | Methods for detecting tissue infiltrating NK cells |
| CA3092522A1 (en) | 2018-03-13 | 2019-09-19 | Innate Pharma | Treatment of head and neck cancer |
| WO2019191764A1 (en) * | 2018-03-28 | 2019-10-03 | Ensemble Group Holdings | Methods of treating cancer in subjects having dysregulated lymphatic systems |
| US20210253694A1 (en) * | 2018-05-15 | 2021-08-19 | Medimmune Limited | Treatment of cancer |
| TW202033555A (zh) | 2018-11-16 | 2020-09-16 | 美商必治妥美雅史谷比公司 | 抗nkg2a抗體及其用途 |
| JP2022553927A (ja) * | 2019-10-14 | 2022-12-27 | イナート・ファルマ・ソシエテ・アノニム | Ｉｌｔ－２阻害剤での癌の処置 |
| MX2023001776A (es) * | 2020-08-12 | 2023-03-10 | Biond Biologics Ltd | Anticuerpos contra ilt2 y uso de los mismos. |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| GB9725764D0 (en) | 1997-12-04 | 1998-02-04 | Isis Innovation | HLA-E binding |
| AU2003232456B2 (en) | 2002-05-30 | 2009-06-04 | Macrogenics, Inc. | CD16A binding proteins and use for the treatment of immune disorders |
| PT2476705E (pt) * | 2004-12-28 | 2016-02-09 | Innate Pharma | Anticorpos monoclonais contra nkg2a |
| CN105315373B (zh) | 2005-05-09 | 2018-11-09 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法 |
| PL1907424T3 (pl) | 2005-07-01 | 2015-12-31 | Squibb & Sons Llc | Ludzkie monoklonalne przeciwciała wobec liganda zaprogramowanej śmierci 1 (PD-L1) |
| JP5829004B2 (ja) | 2006-06-30 | 2015-12-09 | ノボ・ノルデイスク・エー／エス | 抗ｎｋｇ２ａ抗体とその使用 |
| MX2009014199A (es) | 2007-06-18 | 2010-05-24 | Organon Nv | Anticuerpos para el receptor 1 de muerte programada pd-1 de humano. |
| WO2009014708A2 (en) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
| EP2628753A1 (en) | 2008-01-24 | 2013-08-21 | Novo Nordisk A/S | Humanized anti-human NKG2A monoclonal antibody |
| PL2242773T3 (pl) | 2008-02-11 | 2017-11-30 | Cure Tech Ltd. | Przeciwciała monoklonalne do leczenia nowotworu |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| KR101782570B1 (ko) | 2008-12-09 | 2017-09-27 | 제넨테크, 인크. | 항-ｐｄ-ｌ１ 항체 및 ｔ 세포 기능을 향상시키기 위한 그의 용도 |
| EP3279215B1 (en) | 2009-11-24 | 2020-02-12 | MedImmune Limited | Targeted binding agents against b7-h1 |
| EP3409289B1 (en) | 2010-02-26 | 2020-09-30 | Novo Nordisk A/S | Stable antibody containing compositions |
| AU2012245477C1 (en) | 2011-04-20 | 2017-06-15 | Medimmune, Llc | Antibodies and other molecules that bind B7-H1 and PD-1 |
| US9512228B2 (en) | 2011-06-17 | 2016-12-06 | Novo Nordisk A/S | Selective elimination of erosive cells |
| AR087405A1 (es) | 2011-08-01 | 2014-03-19 | Genentech Inc | Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1 e inhibidores de mek |
| SI3081576T1 (sl) | 2013-12-12 | 2019-12-31 | Shanghai Hengrui Pharmaceutical Co., Ltd., | Protitelo PD-1, njegov antigen-vezavni fragment in njegova medicinska uporaba |
| KR20170051462A (ko) | 2014-08-28 | 2017-05-11 | 아카데미슈 지켄후이스 라이덴 | Ｃｄ９４／ｎｋｇ２ａ 및／또는 ｃｄ９４／ｎｋｇ２ｂ 항체, 백신 조합물 |
| SG11201701387SA (en) | 2014-09-16 | 2017-03-30 | Innate Pharma | Treatment regimens using anti-nkg2a antibodies |
| SG11201701340RA (en) * | 2014-09-16 | 2017-03-30 | Innate Pharma | Neutralization of inhibitory pathways in lymphocytes |
| EP3659625A1 (en) | 2014-10-23 | 2020-06-03 | Innate Pharma | Treatment of cancers using anti-nkg2a agents |
-
2017
- 2017-01-20 PT PT177023157T patent/PT3405495T/pt unknown
- 2017-01-20 SI SI201730735T patent/SI3405495T1/sl unknown
- 2017-01-20 DK DK17702315.7T patent/DK3405495T3/da active
- 2017-01-20 CA CA3012055A patent/CA3012055A1/en active Pending
- 2017-01-20 EP EP17702315.7A patent/EP3405495B1/en active Active
- 2017-01-20 EP EP21158066.7A patent/EP3868787A1/en active Pending
- 2017-01-20 US US16/071,499 patent/US10870700B2/en active Active
- 2017-01-20 CN CN201780007833.2A patent/CN108884163B/zh active Active
- 2017-01-20 SG SG11201805831RA patent/SG11201805831RA/en unknown
- 2017-01-20 WO PCT/EP2017/051153 patent/WO2017125532A1/en active Application Filing
- 2017-01-20 KR KR1020187023541A patent/KR20180101549A/ko active Search and Examination
- 2017-01-20 HU HUE17702315A patent/HUE054356T2/hu unknown
- 2017-01-20 PL PL17702315T patent/PL3405495T3/pl unknown
- 2017-01-20 ES ES17702315T patent/ES2871112T3/es active Active
- 2017-01-20 RS RS20210534A patent/RS61901B1/sr unknown
- 2017-01-20 AU AU2017208554A patent/AU2017208554B2/en active Active
- 2017-01-20 CN CN202210915090.1A patent/CN116327916A/zh active Pending
- 2017-01-20 SG SG10202000645SA patent/SG10202000645SA/en unknown
- 2017-01-20 JP JP2018537834A patent/JP7301538B2/ja active Active
- 2017-01-20 RU RU2018125490A patent/RU2769569C2/ru active
- 2017-01-20 LT LTEP17702315.7T patent/LT3405495T/lt unknown
-
2018
- 2018-07-08 IL IL260464A patent/IL260464B/en unknown
-
2020
- 2020-12-21 US US17/128,241 patent/US20210122821A1/en not_active Abandoned
-
2021
- 2021-05-11 CY CY20211100401T patent/CY1124212T1/el unknown
- 2021-05-14 HR HRP20210778TT patent/HRP20210778T1/hr unknown
-
2023
- 2023-06-09 US US18/331,966 patent/US20230303691A1/en active Pending
- 2023-06-21 JP JP2023101829A patent/JP2023134490A/ja active Pending
-
2024
- 2024-04-18 AU AU2024202552A patent/AU2024202552A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201805831RA (en) | Neutralization of inhibitory pathways in lymphocytes | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201811448RA (en) | Dihydropyranopyrimidines for the treatment of viral infections | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201804787UA (en) | Human immunodeficiency virus neutralizing antibodies | |
| SG11201804373VA (en) | Compositions and methods for immunooncology | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201909960UA (en) | Methods for improving memory and cognition and for treating memory and cognitive disorders | |
| SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
| SG11201804263PA (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
| SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones | |
| SG11201808106YA (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
| SG11201901762WA (en) | Methods and composition for the prediction of the activity of enzastaurin | |
| SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11201807523PA (en) | Ilt7 binding molecules and methods of using the same | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201907217RA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201903770UA (en) | Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders | |
| SG11201806424TA (en) | Therapeutic compounds | |
| SG11201806157WA (en) | Method and pharmaceutical composition for treatment of neurodegeneration | |
| SG11201806622PA (en) | Egfl6 specific monoclonal antibodies and methods of their use | |
| SG11201900543SA (en) | Gene therapy for the treatment of aldehyde dehydrogenase deficiency |